ALRN RSI Chart
Last 7 days
-0.5%
Last 30 days
-10.6%
Last 90 days
-19.0%
Trailing 12 Months
171.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2017 | 0 | 0 | 222.0K | 0 |
2016 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | university of texas/texas am investment management co | sold | -85,473 | 4.20741 | -20,315 | - |
Apr 30, 2024 | university of texas/texas am investment management co | sold | -447 | 4.975 | -90.00 | - |
Apr 29, 2024 | university of texas/texas am investment management co | sold | -53,181 | 4.94898 | -10,746 | - |
Mar 05, 2024 | windsor james brian | acquired | - | - | 2,000 | president and coo |
Dec 15, 2023 | windsor james brian | bought | 758 | 3.37 | 225 | president and coo |
Nov 20, 2023 | windsor james brian | bought | 9,987 | 1.9675 | 5,076 | president and coo |
Jan 08, 2021 | satter muneer a | bought | 9,900,000 | 1.1 | 9,000,000 | see remarks |
Which funds bought or sold ALRN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | unchanged | - | 4,477 | 8,288 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | 448 | 829 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -9.25 | 6,606 | 13,393 | -% |
May 15, 2024 | Nantahala Capital Management, LLC | new | - | 1,690,650 | 1,690,650 | 0.10% |
May 15, 2024 | Royal Bank of Canada | new | - | 239,000 | 239,000 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 89,765 | 89,765 | -% |
May 14, 2024 | ICA Group Wealth Management, LLC | unchanged | - | 358 | 663 | -% |
May 14, 2024 | Senvest Management, LLC | new | - | 1,301,210 | 1,301,210 | 0.05% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | added | 60.83 | 214,000 | 299,000 | -% |
May 13, 2024 | FMR LLC | added | 366 | 1,363 | 1,515 | -% |
Unveiling Aileron Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Aileron Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Aileron Therapeutics Inc News
Income Statement (Quarterly) | |||||
Description | (%) Q/Q | 2017Q3 | 2017Q2 | 2016Q3 | 2016Q2 |
Revenue | 475.9% | 167,000 | 29,000 | 10,000 | 16,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -6.4% | 99,192 | 106,008 | 12,822 | 13,991 | 17,157 | 22,007 | 27,232 | 33,770 | 40,255 | 48,481 | 54,768 | 60,531 | 64,671 | 16,341 | 22,239 | 26,125 | 20,373 | 26,473 | 33,952 | 40,193 | 22,399 |
Current Assets | -30.1% | 12,764 | 18,266 | 12,793 | 13,952 | 17,105 | 21,873 | 27,054 | 33,550 | 39,993 | 48,177 | 54,423 | 60,152 | 64,324 | 16,326 | 15,974 | 19,670 | 13,687 | 19,550 | 26,497 | 32,559 | 14,389 |
Cash Equivalents | -30.4% | 12,042 | 17,313 | 12,069 | 13,167 | 7,783 | 5,194 | 4,839 | 7,628 | 7,449 | 3,600 | 7,603 | 10,748 | 19,283 | 7,046 | 7,850 | 17,124 | 10,697 | 5,311 | 6,867 | 10,157 | 11,272 |
Net PPE | -68.4% | 6.00 | 19.00 | 29.00 | 39.00 | 52.00 | 70.00 | 84.00 | 98.00 | 113 | 128 | 144 | 153 | 98.00 | 15.00 | 147 | 164 | 225 | 295 | 361 | 379 | 398 |
Goodwill | 0% | 6,330 | 6,330 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 1.9% | 7,858 | 7,711 | 1,624 | 1,197 | 2,884 | 3,384 | 4,536 | 5,151 | 4,146 | 4,577 | 4,659 | 4,401 | 3,252 | 4,179 | 9,781 | 9,471 | 10,604 | 10,425 | 11,136 | 10,209 | 9,552 |
Current Liabilities | 3.4% | 4,532 | 4,385 | 1,624 | 1,197 | 2,884 | 3,384 | 4,536 | 5,151 | 4,146 | 4,508 | 4,560 | 4,273 | 3,073 | 3,960 | 5,249 | 4,926 | 6,143 | 5,839 | 6,428 | 5,387 | 4,623 |
Shareholder's Equity | -100.0% | - | 6,887 | 11,198 | 12,794 | 14,273 | 18,623 | 22,696 | 28,619 | 36,109 | 43,904 | 50,109 | 56,130 | 61,419 | 12,162 | 12,458 | 16,654 | 9,769 | 16,048 | 22,816 | 29,984 | 12,847 |
Retained Earnings | -2.5% | -295,630 | -288,517 | -281,178 | -279,351 | -277,564 | -272,785 | -268,238 | -261,870 | -253,878 | -245,456 | -238,657 | -231,953 | -226,267 | -219,292 | -214,296 | -209,273 | -204,883 | -198,135 | -190,900 | -183,151 | -175,979 |
Additional Paid-In Capital | 15.2% | 340,340 | 295,376 | 292,285 | 292,056 | 291,756 | 291,365 | 290,941 | 290,499 | 289,971 | 289,282 | 288,674 | 287,987 | 287,603 | 231,412 | 226,715 | 225,890 | 214,625 | 214,148 | 213,671 | 213,083 | 188,811 |
Shares Outstanding | 247.4% | 16,973 | 4,886 | 4,541 | 4,541 | 4,541 | 4,541 | 4,539 | 4,537 | 4,534 | 4,529 | 4,411 | 4,347 | 4,169 | 2,190 | - | - | - | - | - | - | - |
Float | - | - | - | - | 6,587,576 | - | - | - | 19,137,097 | - | - | - | 91,635,955 | - | - | - | 36,630 | - | - | - | 20,008 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 49.3% | -5,271 | -10,391 | -1,640 | -3,116 | -4,661 | -4,409 | -6,971 | -5,685 | -7,800 | -6,255 | -7,260 | -3,763 | -6,476 | -4,689 | -5,043 | -5,072 | -5,672 | -6,305 | -6,976 | -5,692 | -7,501 |
Share Based Compensation | -44.4% | 150 | 270 | 229 | 300 | 391 | 424 | 442 | 528 | 689 | 607 | 660 | 362 | 631 | 363 | 465 | 560 | 505 | 479 | 614 | 460 | 563 |
Cashflow From Investing | 100.0% | - | -96.00 | 542 | 8,500 | 7,250 | 4,764 | 4,182 | 5,864 | 11,649 | 2,251 | 4,089 | -4,798 | -37,459 | -357 | -4,529 | 239 | 11,058 | 4,764 | 3,737 | -19,288 | 7,973 |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | - | 1.00 | 26.00 | 26.00 | 55,604 | 4,242 | 298 | 11,260 | - | -15.00 | -51.00 | 23,865 | 165 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 0 | $ 0 |
Operating expenses: | ||
Research and development | 3,463 | 1,810 |
General and administrative | 3,742 | 2,179 |
Restructuring and other costs | 0 | 1,022 |
Total operating expenses | 7,205 | 5,011 |
Loss from operations | (7,205) | (5,011) |
Other income, net | 92 | 232 |
Net loss | $ (7,113) | $ (4,779) |
Net loss per share - basic | $ (0.86) | $ (1.05) |
Net loss per share - diluted | $ (0.86) | $ (1.05) |
Weighted average common shares outstanding - basic | 8,301,798 | 4,541,167 |
Weighted average common shares outstanding - diluted | 8,301,798 | 4,541,167 |
Comprehensive loss: | ||
Net loss | $ (7,113) | $ (4,779) |
Other comprehensive gain: | ||
Unrealized gain on investments, net of tax of $0 | 0 | 38 |
Total other comprehensive gain | 0 | 38 |
Total comprehensive loss | $ (7,113) | $ (4,741) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 12,042 | $ 17,313 |
Prepaid expenses and other current assets | 697 | 882 |
Restricted cash | 25 | 25 |
Operating lease, right-of-use asset, current portion | 46 | |
Total current assets | 12,764 | 18,266 |
Property and equipment, net | 6 | 19 |
Goodwill | 6,330 | 6,330 |
Intangible assets | 79,200 | 79,200 |
Other non-current assets | 892 | 2,193 |
Total assets | 99,192 | 106,008 |
Current liabilities: | ||
Accounts payable | 2,156 | 1,190 |
Accrued expenses and other current liabilities | 2,376 | 3,147 |
Operating lease liabilities, current portion | 48 | |
Total current liabilities | 4,532 | 4,385 |
Deferred tax liability | 3,326 | 3,326 |
Total liabilities | 7,858 | 7,711 |
Commitments and contingencies (Note 15) | ||
Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at March 31, 2024 and at December 31, 2023; 24,610 shares issued and 12,653 shares outstanding at March 31, 2024 and 24,610 shares issued and outstanding at December 31, 2023 | 46,584 | 91,410 |
Stockholders’ equity: | ||
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and 45,000,000 at December 31, 2023; 16,842,512 shares and 4,885,512 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 103 | 91 |
Additional paid-in capital | 340,340 | 295,376 |
Accumulated other comprehensive loss | (63) | (63) |
Accumulated deficit | (295,630) | (288,517) |
Total liabilities, convertible preferred stock and stockholders' equity | $ 99,192 | $ 106,008 |